Related Experiment Video

Updated: Jun 23, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Glucagon-like peptide-1 and myocardial protection: more than glycemic control

Anjali V Fields1, Brandy Patterson, Ankur A Karnik

  • 1Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

Clinical Cardiology
|May 20, 2009
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) shows promise as a cardioprotective agent, potentially improving myocardial glucose uptake and left ventricular systolic dysfunction in heart failure patients. Further research supports its use in various cardiomyopathies.

Area of Science:

  • Cardiology
  • Metabolic Medicine
  • Pharmacology

Background:

  • Heart failure treatment traditionally targets neurohormonal pathways, but remains a leading cause of morbidity and mortality.
  • Modulating myocardial glucose uptake is an emerging cardioprotective strategy.
  • Glucose-insulin-potassium (GIK) infusions have shown mixed results for acute myocardial infarction.

Purpose of the Study:

  • To review the current evidence on the use of glucagon-like peptide-1 (GLP-1) in treating heart failure.
  • To evaluate GLP-1's efficacy in both animal models and human subjects with cardiomyopathy.
  • To explore GLP-1 as an alternative to traditional heart failure pharmacotherapies.

Main Methods:

  • Review of existing literature on GLP-1 in cardiovascular disease.
  • Analysis of studies involving animal models of cardiac dysfunction.
  • Examination of clinical trials investigating GLP-1 in human patients with heart failure.

Main Results:

  • GLP-1 has demonstrated efficacy in improving left ventricular systolic dysfunction.
  • Evidence suggests GLP-1 may offer cardioprotection in both ischemic and nonischemic cardiomyopathy.
  • GLP-1 represents a potentially more effective alternative to GIK infusions.

Conclusions:

  • GLP-1 is a promising therapeutic agent for heart failure.
  • Targeting myocardial glucose metabolism with GLP-1 offers a novel strategy for cardioprotection.
  • Further investigation into GLP-1's role in managing various cardiomyopathies is warranted.

More Related Videos

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...